Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422454 | 0.82 | EPAS1 (0.39) | TRPV4EPAS1 | |
| SCHEMBL186689 | 0.80 | TRPV4 (0.42) | TRPV4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28069805 | 0.78 | TRPV4 (0.34) | TRPV4EPAS1KDM4EALDH1A1HPGD | |
| SCHEMBL14837971 | 0.78 | EPAS1 (0.31) | TRPV4EPAS1ALDH1A1 | |
| SCHEMBL2728668 | 0.78 | EPAS1 (0.40) | TRPV4EPAS1KDM4EALDH1A1HPGD | |
| SCHEMBL25715391 | 0.78 | NOTUM (0.39) | TRPV4EPAS1KDM4EALDH1A1HPGD | |
| SCHEMBL4323122 | 0.77 | TRPV4 (0.48) | TRPV4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29914996 | 0.76 | TRPV4 (0.39) | TRPV4EPAS1KDM4EALDH1A1HPGD | |
| SCHEMBL27002519 | 0.76 | TRPV4 (0.39) | TRPV4EPAS1KDM4EALDH1A1HPGD | |
| SCHEMBL5109158 | 0.75 | KIF11 (0.39) | KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527830-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2755656-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| US-5314640-A | Tolan derivatives, liquid crystal compositions including same, liquid crystal display devices including the compositions and method of preparation | SEIKO EPSON CORPORATION (JP) | 1994-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235628-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | TRPV4 426/4885EPAS1 1636/4885KDM4E 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.